Agios Pharmaceuticals Stock Price - AGIO

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Agios Pharmaceuticals Inc AGIO NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 36.58 0.00 0.00 0.00 36.58 06:59:54
Bid Price Ask Price Spread Spread % News
0.01 47.00 46.99 99.98% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Agios Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.15B 58.75M $ -346.03M -6.03 - 57.95M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Agios Pharmaceuticals News

Loading Messages....

Latest AGIO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AGIO Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week35.6838.935.5137.7142645k0.92.52%
1 Month43.6143.7533.1737.2587539k-7.03-16.12%
3 Months49.7251.0933.1742.3155546k-13.14-26.43%
6 Months65.0269.6433.1748.6737526k-28.44-43.74%
1 Year72.0179.1733.1754.1463524k-35.43-49.20%
3 Years46.999.824233.1759.1150515k-10.32-22.00%
5 Years47.73138.8533.1766.6173591k-11.15-23.36%

Agios Pharmaceuticals Description

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.


Your Recent History
NASDAQ
AGIO
Agios Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.